Wickham Laboratories announces new microbial identification service
3 November 2015 | By Wickham Laboratories
Introducing the MALDI Biotyper® for rapid microbial identification....
List view / Grid view
News
Black Swan Analysis short-listed for the TVBM 2015 Management Team of the Year Award
3 November 2015 | By Black Swan Analysis
Black Swan Analysis has just been short-listed for the “The Management Team of the Year Award” sponsored by NatWest and open to outstanding management teams in the Thames Valley...
GSK and Merck initiate Phase I trial of GSK3174998 with Keytruda
3 November 2015 | By Victoria White
The trial will evaluate GSK3174998 as monotherapy and in combination with Keytruda in patients with locally advanced, recurrent or metastatic solid tumours that have progressed after standard treatment...
Shire to acquire Dyax; expands HAE pipeline
3 November 2015 | By Victoria White
Shire has announced that it is to acquire Dyax, a company focused on the development of plasma kallikrein inhibitors for the treatment of hereditary angioedema, for approximately $5.9 billion...
Breakthrough Therapy Designation for Keytruda in advanced colorectal cancer
3 November 2015 | By Victoria White
This is the third Breakthrough Therapy Designation granted for Keytruda. The drug was previously granted breakthrough status for advanced melanoma and advanced non-small cell lung cancer (NSCLC)...
Bristol-Myers Squibb to acquire Cardioxyl Pharmaceuticals
3 November 2015 | By Victoria White
The acquisition will give Bristol-Myers Squibb full rights to Cardioxyl’s lead asset CXL-1427...
FDA grants Breakthrough Therapy Designation to pexidartinib for the treatment of TGCT
3 November 2015 | By Victoria White
The Breakthrough Therapy Designation was granted based on results from an extension cohort of a Phase 1 study that assessed the safety and efficacy of pexidartinib...
Boehringer Ingelheim initiates Phase II trial of BI 1482694 in NSCLC
3 November 2015 | By Victoria White
BI 1482694 is a novel, third-generation, oral, irreversible EGFR mutant-specific tyrosine kinase inhibitor (TKI) developed to specifically target tumours with T790M mutations...
EC approves Eylea for myopic choroidal neovascularisation
30 October 2015 | By Victoria White
Bayer plans for an immediate introduction of Eylea to the market with Germany being one of the first launch countries in Europe...
Isis Pharmaceuticals initiates Phase 2 study of ISIS-FXI Rx in ESRD
30 October 2015 | By Victoria White
The Phase 2 study is intended to further characterise the profile of ISIS-FXI Rx and will provide essential data for Bayer's future clinical development programme for ISIS-FXI Rx...
Phase 3 study of CL-108 meets primary endpoints
30 October 2015 | By Victoria White
CL-108 is being developed as a treatment for moderate to severe pain and the prevention of opioid-induced nausea and vomiting (OINV)...
EC approves Vidaza as a new treatment for elderly patients with AML
30 October 2015 | By Victoria White
Dr Hervé Dombret says the 'announcement brings hope to patients with AML, particularly the elderly and more frail patients who cannot undergo intensive therapies'...
Global multiple myeloma treatment market value to rise to $22.4b by 2023
29 October 2015 | By Victoria White
The global multiple myeloma treatment market will rise in value from $8.9 billion in 2014 to an estimated $22.4 billion by 2023, according to research and consulting firm GlobalData...
Pfizer and Allergan considering a merger
29 October 2015 | By Victoria White
Allergan has said that it is in preliminary “friendly discussions” with Pfizer regarding a potential business combination transaction...
FDA approves Yervoy as adjuvant treatment for stage III melanoma
29 October 2015 | By Victoria White
This approval is based on clinical data from a pivotal Phase 3 trial which demonstrated Yervoy significantly improved recurrence-free survival vs. placebo in this setting...
